Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Feb 18;8(2):210-214.
doi: 10.1177/24741264241227684. eCollection 2024 Mar-Apr.

Yttrium-90 Episcleral Plaque Brachytherapy for Choroidal Melanoma

Paul T Finger  1
Affiliations
Case Reports

Yttrium-90 Episcleral Plaque Brachytherapy for Choroidal Melanoma

Paul T Finger. J Vitreoretin Dis. .

Abstract

Purpose: To describe the first use of high-dose-rate yttrium-90 disc brachytherapy for choroidal melanoma. Methods: A 72-year-old patient had a cT1-category choroidal melanoma characterized by the presence of orange pigment, increasing subretinal fluid (SRF), and enlarging tumor thickness. It was treated with single-session, light-guided, light-defined yttrium-90-disc brachytherapy. Results: A specialized handheld applicator provided with 4 encircling lights was used to guide plaque placement and localize treatment. Unlike low-dose-rate plaques, high-dose-rate yttrium-90 required only 3 minutes 39 seconds. In this case, treatment did not require episcleral sutures, muscle relocation, outpatient dwell time, or a second surgery. High-dose-rate treatment improved radiation safety by eliminating perioperative exposure to health care personnel, the community, and the family. At the 13-month follow-up, the SRF and tumor thickness were diminished. There was no secondary cataract, radiation retinopathy, maculopathy, or optic neuropathy, and the visual acuity was 20/20. Conclusions: Yttrium-90 brachytherapy allowed for single-surgery, minimally invasive, outpatient irradiation of a choroidal melanoma.

Keywords: brachytherapy; choroid; high-dose rate; melanoma; plaque; yttrium-90.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Finger is the chief executive officer of and owns private stock in LV Liberty Vision Corp and IP Liberty Vision Corp.

Figures

Figure 1.
Figure 1.
Radiation fields anterior, posterior, and lateral to the yttrium-90 disc are shown. The inset values were calculated from Rivard et al. (Illustration by Toby S. Welles.)
Figure 2.
Figure 2.
(Top left) Fundus photograph (before yttrium-90 high-dose-rate brachytherapy) shows a small inferior choroidal melanoma with orange pigment lipofuscin (arrow). (Top middle) A 3-dimensional optical coherence tomography cross-section of the tumor shows subretinal fluid (SRF) over its apex. (Top right) A midphase fluorescein angiogram shows focal hyperfluorescence corresponding to the previously noted SRF. (Bottom) Early resolution of the orange pigment (left), SRF (middle), and minimally decreased fluorescein hyperfluorescence 13 months after yttrium-90 high-dose-rate brachytherapy.
Figure 3.
Figure 3.
(Top) Lighted nodes on the anterior surface of the iWand P. (Bottom) Lighted nodes in place around the choroidal melanoma. Placement position of the yttrium-90 disc was ensured. (Illustration by Toby S. Welles.)
Figure 4.
Figure 4.
High-dose-rate vs low-dose rate brachytherapy for choroidal melanoma. Abbreviations: 103Pd, palladium-103; 106Ru, ruthenium-106; 125I, iodine-125; 90Sr, strontium-90; 90Y, yttrium-90. Community, outpatient community radiation exposure; Distance rule, the distance a patient is required to stay away from others as an outpatient; Distancing rule, >3 feet away from others required in New York State for 125I and 103Pd, in-patient hospitalization for 106Ru; HDR, high-dose rate; LDR, low-dose rate.
See this image and copyright information in PMC

References

    1. American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com; ABS – OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1-14. doi:10.1016/j.brachy.2013.11.008 - DOI - PubMed
    1. Chiu-Tsao ST, Astrahan MA, Finger PT, et al.. Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. Med Phys. 2012;39(10): 6161-6184. doi:10.1118/1.4749933 - DOI - PubMed
    1. Finger PT, Rivard MJ, Chaugule SS, et al.. Ophthalmic radiotherapy: plaques and implants. In: Chaugule SS, Honavar SG, Finger PT, eds. Surgical Ophthalmic Oncology, A Collaborative Open-Access Reference. Vol. 1. 1st ed. Springer; 2019:147-158.
    1. Finger PT, Moshfeghi DM, Ho TK. Palladium-103 ophthalmic plaque radiotherapy. Arch Ophthalmol. 1991;109(11):1610-1613. doi:10.1001/archopht.1991.01080110148053 - DOI - PubMed
    1. Finger PT, Chin KJ, Duvall G; Palladium-103 for Choroidal Melanoma Study Group. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116(4):790-796.e1. doi:10.1016/j.ophtha.2008.12.027 - DOI - PubMed

Publication types